Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine
NCT ID: NCT00310336
Last Updated: 2010-10-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
30 participants
INTERVENTIONAL
2006-08-31
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Retreatment of non-responders of previous (pegylated) IFNα plus ribavirin therapies with pegylated IFNα plus ribavirin results in a sustained response in less than 10% of the patients.
Extensive analysis of IFNα signaling in cells expressing HCV proteins, in transgenic mice expressing HCV proteins, and in liver biopsies from patients with chronic hepatitis C point to STAT1 methylation as an important posttranslational modification targeted by HCV to inhibit IFNα signaling.
STAT1 methylation can be increased and IFNα can be improved by adding AdoMet and betaine.
The study is designed to test the hypothesis that a combination treatment with pegylated IFNα2b, ribavirin, AdoMet and betaine is superior to the current standard combination therapy with pegylated IFNα plus ribavirin.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
S-adenosyl-L-methionine
betaine
pegylated interferon alpha2b
ribavirin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-responders in previous treatments with IFNα plus ribavirin or pegylated IFNα plus ribavirin.
* Elevated ALT-levels on at least two occasions during \>6 months preceding entry.
* Detection of HCV RNA in serum (PCR).
* Compensated liver disease (Child-Pugh A) and a Child-Pugh score \<5.
* The following minimal hematologic and biochemical criteria:
* Hemoglobin for males and females \>11g/dl
* Absolute Neutrophil count \>1500 cells/mm3
* Platelets \>75'000/mm3
* HBs Ag negative.
* ANA \<1:320, and no evidence for autoimmune hepatitis.
* α-Fetoprotein \<50μg/l (when between upper limit of normal and 50μg/l, ultrasonographical exclusion of hepatocellular carcinoma (HCC) is needed).
* Fasting blood glucose within normal limits, if history of diabetes or hypertension, a pre-therapy ocular examination is indicated.
* TSH within normal limits or adequately controlled.
* Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 2-3 week period prior to the first dose of study drug. Additionally, all fertile males and females must be using effective contraception during treatment and during the 6 months after treatment end. This may include, but is not limited to, using birth control pills, IUDs, condoms, diaphragms, or implants, being surgically sterilized, or being in a post-menopausal state.
* Willingness to give written informed consent and willingness to participate to and comply with the study
Exclusion Criteria
* Positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, HBe Ag.
* Positive test at screening for HIV.
* History or other evidence of a medical condition associated with chronic liver disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures).
* Hypersensitivity to study drugs.
* Participation in any other clinical trial within 30 days of entry into this protocol.
* Treatment with any investigational drug within 30 days of entry into this protocol.
* History or evidence of decompensated liver disease (Child-Pugh B/C) and a Child-Pugh score \>5. Ascites, coagulopathy, hyperbilirubinemia, hepatic encephalopathy, or hypoalbuminemia and a Child-Pugh score \>5 are conditions consistent with decompensated liver disease.
* History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease.
* Hepatocellular carcinoma (HCC) or α-Fetoprotein \>50μg/l.
* Patients with organ transplants other than cornea and hair transplant.
* Therapy with any antisystemic or immunomodulatory treatment (including supra-physiologic doses of steroids or radiation) \<6 months prior the first dose of study drug
* Hemoglobinopathy (e.g. thalassemia) or any other cause of or tendency for hemolysis.
* Any known preexisting medical condition that could interfere with the patient's participation in and completion of the study such as:
* Preexisting psychiatric condition, especially depression, or a history of severe psychiatric disorder, such as major psychosis, suicidal ideation and/or suicidal attempts (based on a mandatory psychiatric advice).
* CNS trauma or active seizure disorders requiring medication.
* Significant cardiovascular dysfunction.
* Poorly controlled diabetes mellitus.
* Renal dysfunction, i.e. serum creatinine levels \>1.5 times upper limit of normal.
* Autoimmune diseases.
* Evidence of severe retinopathy (e.g. CMV retinitis, macular degeneration).
* Any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids.
* Clinical gout.
* Important substance abuse (alcohol \>80 g/d, i.v. drugs etc.).
* Active opportunistic infections.
* Non-Hodgkin lymphoma or Hodgkin lymphoma.
* Kaposi sarcoma.
* Inability or unwillingness to provide informed consent or abide by the requirements of the study.
* Male partners of pregnant women.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Basel, Switzerland
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Markus H Heim, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Basel, Switzerland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Basel
Basel, Canton of Basel-City, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Duong FH, Christen V, Filipowicz M, Heim MH. S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro. Hepatology. 2006 Apr;43(4):796-806. doi: 10.1002/hep.21116.
Duong FH, Christen V, Berke JM, Penna SH, Moradpour D, Heim MH. Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1. J Virol. 2005 Dec;79(24):15342-50. doi: 10.1128/JVI.79.24.15342-15350.2005.
Duong FH, Filipowicz M, Tripodi M, La Monica N, Heim MH. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology. 2004 Jan;126(1):263-77. doi: 10.1053/j.gastro.2003.10.076.
Blindenbacher A, Duong FH, Hunziker L, Stutvoet ST, Wang X, Terracciano L, Moradpour D, Blum HE, Alonzi T, Tripodi M, La Monica N, Heim MH. Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology. 2003 May;124(5):1465-75. doi: 10.1016/s0016-5085(03)00290-7.
Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol. 1999 Oct;73(10):8469-75. doi: 10.1128/JVI.73.10.8469-8475.1999.
Filipowicz M, Bernsmeier C, Terracciano L, Duong FH, Heim MH. S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. PLoS One. 2010 Nov 8;5(11):e15492. doi: 10.1371/journal.pone.0015492.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EKBB 37/06
Identifier Type: -
Identifier Source: org_study_id